Recommend Cell Adhesion & Migration (CAM) to your librarian for 2008. Download form here.

Sign up for TOC Alerts.

home subscribe search archive forthcoming

Email this page Print this page

Review

Neuropilins: Novel Targets for Anti-Angiogenesis Therapies

Elena Geretti and Michael Klagsbrun

volume 1 | issue 2

April/May/June 2007
Pages: 56 - 61

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

It is now well established that neuropilins (NRP1 and NRP2), first described as mediators of neuronal guidance, are also mediators of angiogenesis and tumor progression. NRPs are receptors for the class-3 semaphorin (SEMA) family of axon guidance molecules and also for the vascular endothelial growth factor (VEGF) family of angiogenic factors. VEGF-NRP interactions promote developmental angiogenesis as shown in mouse knockout and zebrafish knockdown studies. There is also evidence that NRPs mediate tumor progression. For example, overexpression of NRP1 enhances tumor growth whereas NRP1 antagonists, such as soluble NRP1 and anti-NRP1 antibodies, inhibit tumor growth. Furthermore, some class-3 SEMAs acting via NRPs inhibit tumor angiogenesis, progression and metastasis. Clinical data suggest that high NRP levels correlate with poor prognosis and survival in a variety of cancer types. Taken together, these results suggest that NRPs are potentially valuable targets for new anti-cancer therapies. We analyze here the current knowledge on NRPs and their role in angiogenesis and tumor progression and enumerate strategies for targeting these receptors.

Authors

Elena Geretti

Department of Surgery, Vascular Biology Program, Children's Hospital and Harvard Medical School, Boston, MA

Michael Klagsbrun

Departments of Surgery and Pathology, Vascular Biology Program, Children's Hospital and Harvard Medical School, Boston, MA



We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.